Cipla Receives 'Buy' Rating from MarketsMOJO, Strong Financial Performance Drives Upgrade
Cipla, a leading pharmaceutical and drug company, has recently received a 'Buy' rating from MarketsMOJO on October 29, 2024. This upgrade comes as a result of the company's strong financial performance and positive results in the last 6 consecutive quarters.One of the key factors contributing to this upgrade is Cipla's low Debt to Equity ratio, which is currently at 0 times, indicating a healthy financial position. Additionally, the company has shown a consistent growth in its operating profit, with an annual rate of 23.19%. This is a positive sign for investors looking for long-term growth opportunities.
In terms of financial performance, Cipla has achieved its highest net sales of Rs 7,051.02 crore and PBDIT of Rs 1,885.59 crore in the last quarter. The company's operating profit to net sales ratio is also at its highest at 26.74%, showcasing its strong operational efficiency.
From a technical standpoint, the stock is currently in a Mildly Bullish range, with multiple indicators such as RSI, MACD, KST, DOW, and OBV showing a bullish trend. This further supports the 'Buy' rating for the stock.
Moreover, Cipla has an attractive valuation with a Price to Book Value of 4.5 and a ROE of 16. This indicates that the stock is trading at a fair value compared to its historical valuations. In the past year, the stock has generated a return of 25.92%, while its profits have increased by 37.2%. This is reflected in the company's low PEG ratio of 0.7, making it an attractive investment opportunity.
Another positive aspect of Cipla is its high institutional holdings at 52.97%. This shows that institutional investors have a better capability and resources to analyze the fundamentals of the company, making it a reliable choice for investors.
In conclusion, with its strong financial performance, positive results, and attractive valuation, Cipla is a 'Buy' for investors looking for a stable and profitable investment in the pharmaceutical and drug industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
{{text.big_txt}}
{{text .small_txt}}
{{dashverdictresult.dashboard.stock_details.short_name}}
SEND BY EMAIL
Register now to see if the stock’s characteristics match your investment style
Subscribe now to see if the stock's characteristics match your investment style
{{dashverdictresult.dashboard.risk_return_voltality.risk_type}}, {{dashverdictresult.dashboard.risk_return_voltality.return_type}}
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
Create your portfolio and know how much should this stock be in your portfolio
Subscribe now to know how much you should hold in this stock
We have found 2 better stocks that you can consider
{{dashverdictresult.dashboard.return_text}}
Investors Returns (3 years) –
| Period | 6M | 1Y | 2Y | 3Y |
| {{ keyd.val }} | ||||
| {{ keyd.val }} |
Quality: {{dashverdictresult.dashboard.dotsummary.q_txt}}
Valuation: {{dashverdictresult.dashboard.dotsummary.v_txt}}
Quarterly Financial Trend: {{dashverdictresult.dashboard.dotsummary.f_txt}}
Technicals: {{dashverdictresult.dashboard.dotsummary.tech_txt}}
Stock Info:
BSE – {{dashverdictresult.dashboard.stock_details.scripcode}}/ NSE – {{dashverdictresult.dashboard.stock_details.symbol}}
Market Cap – {{dashverdictresult.dashboard.priceinfo.mcap_class}} (Rs. {{dashverdictresult.dashboard.priceinfo.mcap| number :0}} cr)
Sector – {{dashverdictresult.dashboard.stock_details.ind_name}}
52 w H/L (Rs.) – {{dashverdictresult.dashboard.priceinfo.wk_high52}}/{{dashverdictresult.dashboard.priceinfo.wk_low52}}
Average vol (6M) – {{dashverdictresult.dashboard.priceinfo.vol}}
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
